RT Journal Article
SR Electronic
T1 Discovery and Validation of Salivary Extracellular RNA Biomarkers for Noninvasive Detection of Gastric Cancer
JF Clinical Chemistry
JO Clin. Chem.
FD American Association for Clinical Chemistry
SP 1513
OP 1521
DO 10.1373/clinchem.2018.290569
VO 64
IS 10
A1 Li, Feng
A1 Yoshizawa, Janice M.
A1 Kim, Kyoung-Mee
A1 Kanjanapangka, Julie
A1 Grogan, Tristan R.
A1 Wang, Xiaoyan
A1 Elashoff, David E.
A1 Ishikawa, Shigeo
A1 Chia, David
A1 Liao, Wei
A1 Akin, David
A1 Yan, Xinmin
A1 Lee, Min-Sun
A1 Choi, Rayun
A1 Kim, Su-Mi
A1 Kang, So-Young
A1 Bae, Jae-Moon
A1 Sohn, Tae-Sung
A1 Lee, Jun-Ho
A1 Choi, Min-Gew
A1 Min, Byung-Hoon
A1 Lee, Jun-Haeng
A1 Kim, Jae J.
A1 Kim, Yong
A1 Kim, Sung
A1 Wong, David T.W.
YR 2018
UL http://clinchem.aaccjnls.org/content/64/10/1513.abstract
AB BACKGROUND: Biomarkers are needed for noninvasive early detection of gastric cancer (GC). We investigated salivary extracellular RNA (exRNA) biomarkers as potential clinical evaluation tools for GC.METHODS: Unstimulated whole saliva samples were prospectively collected from 294 individuals (163 GC and 131 non-GC patients) who underwent endoscopic evaluation at the Samsung Medical Center in Korea. Salivary transcriptomes of 63 GC and 31 non-GC patients were profiled, and mRNA biomarker candidates were verified with reverse transcription quantitative real-time PCR (RT-qPCR). In parallel, microRNA (miRNA) biomarkers were profiled and verified with saliva samples from 10 GC and 10 non-GC patients. Candidate biomarkers were validated with RT-qPCR in an independent cohort of 100/100 saliva samples from GC and non-GC patients. Validated individual markers were configured into a best performance panel.RESULTS: We identified 30 mRNA and 15 miRNA candidates whose expression pattern associated with the presence of GC. Among them, 12 mRNA and 6 miRNA candidates were verified with the discovery cohort by RT-qPCR and further validated with the independent cohort (n = 200). The configured biomarker panel consisted of 3 mRNAs (SPINK7, PPL, and SEMA4B) and 2 miRNAs (MIR140-5p and MIR301a), which were all significantly down-regulated in the GC group, and yielded an area under the ROC curve (AUC) of 0.81 (95% CI, 0.72–0.89). When combined with demographic factors, the AUC of the biomarker panel reached 0.87 (95% CI, 0.80–0.93).CONCLUSIONS: We have discovered and validated a panel of salivary exRNA biomarkers with credible clinical performance for the detection of GC. Our study demonstrates the potential utility of salivary exRNA biomarkers in screening and risk assessment for GC.